Rapt Therapeutics Stock Last Dividend Paid

RAPT Stock

USD 1.09 0.08 6.84%

RAPT Therapeutics fundamentals help investors to digest information that contributes to RAPT Therapeutics' financial success or failures. It also enables traders to predict the movement of RAPT Stock. The fundamental analysis module provides a way to measure RAPT Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to RAPT Therapeutics stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

RAPT Therapeutics Company Last Dividend Paid Analysis

RAPT Therapeutics' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.

Last Dividend

Last Profit Distribution Amount

Total Shares

More About Last Dividend Paid | All Equity Analysis

RAPT Last Dividend Paid Driver Correlations

Understanding the fundamental principles of building solid financial models for RAPT Therapeutics is extremely important. It helps to project a fair market value of RAPT Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since RAPT Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of RAPT Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of RAPT Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Capital Stock	Current Deferred Revenue	Short Term Debt	Short Term Investments	Deferred Long Term Liab
Total Assets		0.95	0.89	0.57	-0.85	0.77	0.89	-0.72	0.95	1.0	1.0	0.91	0.26	0.87	-0.89	0.74	0.92	-0.76
Total Stockholder Equity	0.95		0.87	0.41	-0.84	0.76	0.87	-0.9	1.0	0.95	0.94	0.96	0.53	0.8	-0.81	0.75	0.81	-0.71
Net Tangible Assets	0.89	0.87		0.46	-0.97	0.83	1.0	-0.72	0.87	0.89	0.87	0.9	0.2	0.88	-0.91	0.79	0.77	-0.91
Net Debt	0.57	0.41	0.46		-0.42	0.42	0.45	-0.12	0.41	0.58	0.59	0.36	-0.33	0.49	-0.51	0.67	0.54	-0.4
Retained Earnings	-0.85	-0.84	-0.97	-0.42		-0.9	-0.99	0.7	-0.84	-0.84	-0.82	-0.91	-0.2	-0.91	0.92	-0.74	-0.73	0.95
Accounts Payable	0.77	0.76	0.83	0.42	-0.9		0.85	-0.61	0.76	0.76	0.73	0.87	0.17	0.88	-0.79	0.57	0.54	-0.8
Capital Surpluse	0.89	0.87	1.0	0.45	-0.99	0.85		-0.72	0.87	0.88	0.86	0.91	0.21	0.89	-0.93	0.78	0.78	-0.93
Total Liab	-0.72	-0.9	-0.72	-0.12	0.7	-0.61	-0.72		-0.9	-0.72	-0.7	-0.87	-0.82	-0.56	0.58	-0.64	-0.53	0.54
Net Invested Capital	0.95	1.0	0.87	0.41	-0.84	0.76	0.87	-0.9		0.95	0.94	0.96	0.53	0.8	-0.81	0.75	0.81	-0.71
Total Current Assets	1.0	0.95	0.89	0.58	-0.84	0.76	0.88	-0.72	0.95		1.0	0.9	0.26	0.86	-0.89	0.75	0.92	-0.75
Net Working Capital	1.0	0.94	0.87	0.59	-0.82	0.73	0.86	-0.7	0.94	1.0		0.88	0.25	0.85	-0.88	0.75	0.93	-0.73
Common Stock	0.91	0.96	0.9	0.36	-0.91	0.87	0.91	-0.87	0.96	0.9	0.88		0.47	0.9	-0.87	0.77	0.73	-0.81
Property Plant Equipment	0.26	0.53	0.2	-0.33	-0.2	0.17	0.21	-0.82	0.53	0.26	0.25	0.47		0.06	-0.07	0.19	0.1	-0.04
Capital Stock	0.87	0.8	0.88	0.49	-0.91	0.88	0.89	-0.56	0.8	0.86	0.85	0.9	0.06		-0.96	0.74	0.77	-0.9
Current Deferred Revenue	-0.89	-0.81	-0.91	-0.51	0.92	-0.79	-0.93	0.58	-0.81	-0.89	-0.88	-0.87	-0.07	-0.96		-0.79	-0.87	0.95
Short Term Debt	0.74	0.75	0.79	0.67	-0.74	0.57	0.78	-0.64	0.75	0.75	0.75	0.77	0.19	0.74	-0.79		0.65	-0.73
Short Term Investments	0.92	0.81	0.77	0.54	-0.73	0.54	0.78	-0.53	0.81	0.92	0.93	0.73	0.1	0.77	-0.87	0.65		-0.73
Deferred Long Term Liab	-0.76	-0.71	-0.91	-0.4	0.95	-0.8	-0.93	0.54	-0.71	-0.75	-0.73	-0.81	-0.04	-0.9	0.95	-0.73	-0.73

Click cells to compare fundamentals

Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.

Competition

Predict RAPT Therapeutics

RAPT Dividend Paid And Capex Coverage Ratio

Dividend Paid And Capex Coverage Ratio

(90.58)

At this time, RAPT Therapeutics' Dividend Paid And Capex Coverage Ratio is comparatively stable compared to the past year.

Based on the recorded statements, RAPT Therapeutics has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Financial Widgets Now

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets

All Next

Launch Module

RAPT Fundamentals

	Return On Equity	-0.8
	Return On Asset	-0.47
	Current Valuation	(51.88 M)
	Shares Outstanding	34.96 M
	Shares Owned By Insiders	1.84 %
	Shares Owned By Institutions	86.66 %
	Number Of Shares Shorted	1.66 M
	Price To Book	0.40 X
	Price To Sales	411.22 X
	Gross Profit	1.53 M
	EBITDA	(125.85 M)
	Net Income	(116.8 M)
	Cash And Equivalents	207.34 M
	Cash Per Share	6.99 X
	Total Debt	6.91 M
	Debt To Equity	0.04 %
	Current Ratio	15.97 X
	Book Value Per Share	2.74 X
	Cash Flow From Operations	(97.05 M)
	Short Ratio	1.32 X
	Earnings Per Share	(2.78) X
	Target Price	2.5
	Number Of Employees	70
	Beta	0.32
	Market Capitalization	40.9 M
	Total Asset	173.33 M
	Retained Earnings	(484.68 M)
	Working Capital	139.95 M
	Current Asset	17 K
	Current Liabilities	167 K
	Net Asset	173.33 M

About RAPT Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze RAPT Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RAPT Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RAPT Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC